208 related articles for article (PubMed ID: 11012558)
41. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
Balavoine F; Azizi M; Bergerot D; De Mota N; Patouret R; Roques BP; Llorens-Cortes C
Clin Pharmacokinet; 2014 Apr; 53(4):385-95. PubMed ID: 24337978
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
43. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
Miceli JJ; Wilner KD; Hansen RA; Johnson AC; Apseloff G; Gerber N
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):5S-13S. PubMed ID: 10771448
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses.
Rogers SL; Cooper NM; Sukovaty R; Pederson JE; Lee JN; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):7-12. PubMed ID: 9839759
[TBL] [Abstract][Full Text] [Related]
45. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
[TBL] [Abstract][Full Text] [Related]
46. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.
Tiseo PJ; Foley K; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):45-50. PubMed ID: 9839766
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration.
Tiseo PJ; Rogers SL; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):13-8. PubMed ID: 9839760
[TBL] [Abstract][Full Text] [Related]
48. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
49. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
[TBL] [Abstract][Full Text] [Related]
50. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
[TBL] [Abstract][Full Text] [Related]
51. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
[TBL] [Abstract][Full Text] [Related]
53. Objective measures in determining the central effectiveness of a new antihypoxidotic SL-76188: pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly.
Grünberger J; Saletu B; Linzmayer L; Stöhr H
Arch Gerontol Geriatr; 1982 Nov; 1(3):261-85. PubMed ID: 6764605
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
55. The influence of age and gender on the pharmacokinetics of moxifloxacin.
Sullivan JT; Lettieri JT; Liu P; Heller AH
Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
[TBL] [Abstract][Full Text] [Related]
56. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
[TBL] [Abstract][Full Text] [Related]
57. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
59. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
[TBL] [Abstract][Full Text] [Related]
60. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
